Biotechnology company Gero has secured $6M in a Series A extension round led by Melnichek Investments. The funding will enable Gero to expand its scientific team, further its drug development efforts, and increase its US presence. Gero uses generative AI tools to analyze real-world health data to develop cures for age-related diseases. Earlier this year, they announced a research collaboration with Pfizer and are in discussions with other pharmaceutical companies interested in the growing market of age-related diseases. Gero looks to separate the effects of aging from the effects of disease, primarily through large health models (LHMs), which help predict human health outcomes. They are planning another funding round soon and inviting potential investors to engage in early discussions.
To read more, click here.
[Source: BioSpace, October 18th, 2023]